Maignen FM - Search Results

1

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.

Blagden SP, Billingham L, Brown LC, Buckland SW, Cooper AM, Ellis S, Fisher W, Hughes H, Keatley DA, Maignen FM, Morozov A, Navaie W, Pearson S, Shaaban A, Wydenbach K, Kearns PR; Experimental Cancer Medicine Centres (ECMC) CID trials working group. Blagden SP, et al. Among authors: maignen fm. Br J Cancer. 2020 Feb;122(4):473-482. doi: 10.1038/s41416-019-0653-9. Epub 2020 Jan 6. Br J Cancer. 2020. PMID: 31907370 Free PMC article. Review.

2

Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.

Maignen F, Osipenko L, Pinilla-Dominguez P, Crowe E. Maignen F, et al. Eur J Clin Pharmacol. 2017 Mar;73(3):297-305. doi: 10.1007/s00228-016-2174-2. Epub 2016 Dec 10. Eur J Clin Pharmacol. 2017. PMID: 27942759

3

Trends In Early Engagement Between Industry And HTA: Analysis of Scientific Advice Service Provided By Nice Since 2009.

Maignen FM, Osipenko L, Gajraj E, Chivers R. Maignen FM, et al. Value Health. 2014 Nov;17(7):A441. doi: 10.1016/j.jval.2014.08.1159. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201182 Free article. No abstract available.

4

Regulatory watch: Outcomes of early health technology assessment dialogues in medicinal product development.

Maignen F, Osipenko L, Pinilla-Dominguez P, Crowe E. Maignen F, et al. Nat Rev Drug Discov. 2017 Feb 2;16(2):79. doi: 10.1038/nrd.2016.286. Nat Rev Drug Discov. 2017. PMID: 28148947 No abstract available.

5

Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.

Lacombe D, Bogaerts J, Tombal B, Maignen F, Osipienko L, Sullivan R, Golfinopoulos V. Lacombe D, et al. Mol Oncol. 2019 Mar;13(3):558-566. doi: 10.1002/1878-0261.12431. Epub 2019 Jan 19. Mol Oncol. 2019. PMID: 30561901 Free PMC article. Review.

6

How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

Cooper S, Bouvy JC, Baker L, Maignen F, Jonsson P, Clark P, Palmer S, Boysen M, Crabb N. Cooper S, et al. BMJ. 2020 Jan 2;368:l6435. doi: 10.1136/bmj.l6435. BMJ. 2020. PMID: 31896539 No abstract available.

7

Comparing access to orphan medicinal products in Europe.

Zamora B, Maignen F, O'Neill P, Mestre-Ferrandiz J, Garau M. Zamora B, et al. Orphanet J Rare Dis. 2019 May 3;14(1):95. doi: 10.1186/s13023-019-1078-5. Orphanet J Rare Dis. 2019. PMID: 31053154 Free PMC article.

8

Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.

Alvarez Y, Hidalgo A, Maignen F, Slattery J. Alvarez Y, et al. Drug Saf. 2010 Jun 1;33(6):475-87. doi: 10.2165/11534410-000000000-00000. Drug Saf. 2010. PMID: 20486730

9

A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality.

Maignen F, Hauben M, Dogné JM. Maignen F, et al. Ther Adv Drug Saf. 2017 Jul;8(7):231-244. doi: 10.1177/2042098617704143. Epub 2017 May 5. Ther Adv Drug Saf. 2017. PMID: 28845231 Free PMC article.

10

Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.

Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Maignen F, et al. Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):195-207. doi: 10.1002/pds.3529. Epub 2013 Nov 15. Pharmacoepidemiol Drug Saf. 2014. PMID: 24243665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters